Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01881789
Recruitment Status : Completed
First Posted : June 20, 2013
Last Update Posted : October 17, 2019
Sponsor:
Information provided by (Responsible Party):
Amgen

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Phase 1b:

  • To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide
  • To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide

Phase 2:

  • To estimate the overall response rate (ORR) and complete response rate (CRR)
  • To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide

Secondary Objectives:

  • To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with dexamethasone and lenalidomide or oral cyclophosphamide
  • To estimate the duration of response (DOR)
  • To estimate progression-free survival (PFS)

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Oprozomib Drug: Lenalidomide Drug: Dexamethasone Drug: Cyclophosphamide Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Study Start Date : August 2013
Actual Primary Completion Date : September 23, 2019
Actual Study Completion Date : September 23, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Oprozomib, Lenalidomide and Dexamethasone (ORd)
Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15,16, 22 and 23 in combination with lenalidomide at a dose of 25 mg on Days 1-21, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles.
 Drug: Oprozomib
Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
Other Name: Oprozomib ER tablets

Drug: Lenalidomide
Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles
Other Name: Revlimid

Drug: Dexamethasone
Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles
Experimental: Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)
Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15, 16, 22 and 23 in combination with oral cyclophosphamide at a dose of 300 mg/m2 on Days 1, 8, and 15, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles
 Drug: Oprozomib
Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
Other Name: Oprozomib ER tablets

Drug: Dexamethasone
Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles

Drug: Cyclophosphamide
Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles
Other Name: Cytoxan


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: 6 months ]
    For each dosing schedule, the MTD will be defined as the highest dose at which a DLT is observed in fewer than 2 of 6 patients. DLT is defined as any of the following treatment-related events occurring in the first 28 days of treatment.

  2. Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 36 months ]
    Safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as defined by the type, incidence, severity, and outcome of Adverse Events (AEs).

  3. Overall Response Rate (ORR) [ Time Frame: 14 months ]
    The antitumor activity of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as measured by overall response rate (ORR).

  4. Complete Response Rate (CRR) [ Time Frame: 17 months ]
    The antitumor activity of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as measured by complete response rate (CRR).


Secondary Outcome Measures :
  1. Population Pharmacokinetic (PK) Parameters - Apparent Clearance [ Time Frame: 18 months ]
    The Apparent Clearance is defined as the amount of drug administered (dose) divided by the plasma concentration-time curve (AUC) of oprozomib and its metabolites at various time points.

  2. Population Pharmacokinetic (PK) Parameters - Volume of Distribution [ Time Frame: 18 months ]
    The Volume of Distribution is defined as the amount of oprozomib administered (dose) divided by initial oprozomib plasma concentration.

  3. Duration of Response (DOR) [ Time Frame: 42 months ]
    Duration of Response is defined as the time from first evidence of partial response (PR) or better to confirmation of disease progression or death due to any cause.

  4. Progression-Free Survival (PFS) [ Time Frame: 42 months ]
    Progression-Free Survival is defined as the time from the start of treatment to disease progression or death (due to any cause), whichever comes first.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Newly diagnosed, symptomatic multiple myeloma patients for whom treatment is indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant, with measurable disease
  • Creatinine clearance of ≥ 50 mL/min (measured or calculated using the Cockcroft and Gault formula)

Key Exclusion Criteria:

  • Any prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a total dose of 160 mg or equivalent within 14 days prior to the first dose of study treatment). Use of topical or inhaled steroids is acceptable
  • Radiation therapy within 2 weeks prior to first dose
  • Major surgery within 3 weeks prior to first dose
  • Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose
  • Clinical significant gastrointestinal bleeding in the 6 months prior to Cycle 1 Day 1 (C1D1) first dose
  • Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of first dose
  • Other malignancy within the past 3 years except those considered cured by surgical resection including some cases of: with the exception of adequately treated basal or squamous cell carcinoma of the skin, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the breast or cervix, carcinoma in situ of the breast, prostate cancer with Gleason Score 6 or less with stable prostate specific antigen levels., or cancer considered cured by surgical resection
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01881789


Locations
Layout table for location information
United States, Alabama
Clearview Cancer Institute
Huntsville, Alabama, United States
United States, California
Providence St. Joseph's Hospital
Burbank, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Monterey Bay Oncology Corp DBA Pacific Cancer Care
Salinas, California, United States
United States, Colorado
Colorado Blood Cancer Institute
Denver, Colorado, United States
United States, Florida
H. Lee Moffit Cancer Center & Research Institute
Tampa, Florida, United States
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States
United States, Indiana
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
United States, Maryland
Center for Cancer & Blood Disorders
Bethesda, Maryland, United States
United States, North Carolina
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States
United States, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
United States, Wisconsin
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01881789     History of Changes
Other Study ID Numbers: OPZ003
First Posted: June 20, 2013    Key Record Dates
Last Update Posted: October 17, 2019
Last Verified: October 2019
Keywords provided by Amgen:
multiple myeloma
proteasome inhibitor
oprozomib
orpozomib tablets
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
 Dexamethasone acetate
Cyclophosphamide
Lenalidomide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents